---
title: "Adjunctive pharmacological and non‑pharmacological treatments for negative symptoms of schizophren"
id: "medrxiv-16-comparative-efficacy-of-pharmacological-and-non-pharmacological-adjunctive"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-16-comparative-efficacy-of-pharmacological-and-non-pharmacological-adjunctive"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.29.26359223v1?rss=1"
published_at: "2026-07-31T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Adjunctive pharmacological and non‑pharmacological treatments for negative symptoms of schizophren
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-16-comparative-efficacy-of-pharmacological-and-non-pharmacological-adjunctive
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.29.26359223v1?rss=1)
- **Published At:** 2026-07-31T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This systematic review and network meta-analysis compared **pharmacological** and **non‑pharmacological adjunctive** treatments for adults with prominent or persistent **negative symptoms** of schizophrenia or schizoaffective disorder receiving stable antipsychotic treatment. - The review followed PRISMA 2020 and PRISMA‑NMA reporting standards and was registered in PROSPERO (CRD420261422218). Databases searched included PubMed, Europe PMC, Semantic Scholar and Crossref to 29 July 2026, plus citation chasing. - Eligible studies were randomized controlled trials in adults meeting DSM/ICD criteria, with prominent or persistent negative symptoms, stable antipsychotic treatment, and an adjunctive intervention. Outcomes used were PANSS negative subscale or SANS scores. - Forty‑nine unique RCTs met clinical and design criteria. A locked quantitative dataset included 28 trials (2,067 randomized; 1,933 analysable participants); the primary connected network contained 24 trials, 25 treatments and 31 comparisons. - Random‑effects frequentist network meta‑analysis estimated standardized mean differences (SMDs) with 95% CIs; negative SMDs favoured the add‑on treatment. Heterogeneity was reported as low (τ = 0.119; τ2 = 0.014). - Fourteen add‑on interventions had confidence intervals excluding the null versus a broad control node. Highest P‑scores were observed for **mirtazapine** (SMD −2.38), **granisetron** (−1.96), **tropisetron** (−1.82), **minocycline** (−1.78) and **memantine** (−1.54). - Several **non‑pharmacological** adjuncts showed efficacy signals versus broad control, including **tDCS**, **rTMS** and body‑oriented psychotherapy. - The evidence network was predominantly star‑shaped, with most nodes informed by single small trials; direct active comparisons were scarce and inconsistency could not be estimated (zero inconsistency degrees of freedom). - Risk of bias (RoB 2) judgments were low for eight trials, some concerns for 15 and high for five. The authors caution that the treatment hierarchy is hypothesis‑generating and not sufficient for firm clinical recommendations. - As a preprint, the study has not been peer reviewed and should not be used alone to guide clinical practice.
## Clinical Analysis & Structured Key Points
Comparative efficacy of pharmacological and non-pharmacological adjunctive treatments for prominent or persistent negative symptoms of schizophrenia: a systematic review and network meta-analysis | medRxiv Skip to main content Comparative efficacy of pharmacological and non-pharmacological adjunctive treatments for prominent or persistent negative symptoms of schizophrenia: a systematic review and network meta-analysis View ORCID Profile chenkai yangyang , Jia Chen , Xiaoqiang Xiao , Yifan Li , Hongjun Du , Wenjiao Min , Xu Zhang doi: https://doi.org/10.64898/2026.07.29.26359223 chenkai yangyang Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for chenkai yangyang Jia Chen Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site Xiaoqiang Xiao Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yifan Li Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hongjun Du Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site Wenjiao Min Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site Xu Zhang Sichuan Provincial Center for Mental Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: zhangxu{at}med.uestc.edu.cn Abstract Info/History Metrics Data/Code Preview PDF Abstract Abstract Background Negative symptoms are persistent determinants of disability in schizophrenia and often respond incompletely to antipsychotic treatment. Objective To compare the efficacy of pharmacological and non-pharmacological add-on treatments for prominent or persistent negative symptoms using network meta-analysis. Methods This systematic review followed PRISMA 2020 and PRISMA-NMA and was registered in PROSPERO (CRD420261422218). PubMed, Europe PMC, Semantic Scholar and Crossref were searched from inception to 29 July 2026, supplemented by citation chasing. Eligible studies were randomized controlled trials in adults with DSM/ICD schizophrenia or schizoaffective disorder, prominent or persistent negative symptoms, stable antipsychotic treatment and an adjunctive intervention. Outcomes were Positive and Negative Syndrome Scale negative subscale or Scale for the Assessment of Negative Symptoms scores. Random-effects frequentist networks estimated standardized mean differences (SMDs) with 95% confidence intervals (CIs); negative values favoured add-on treatment. Risk of bias was assessed with Cochrane RoB 2. Results Forty-nine unique RCTs met the clinical and design criteria, of which 28 (2,067 randomized; 1,933 analysable participants) contributed to the locked quantitative dataset. The primary connected network included 24 trials, 25 treatments and 31 comparison estimates. Fourteen add-ons had CIs excluding the null versus a broad control node. The highest P-scores were observed for mirtazapine (SMD −2.38, 95% CI −3.55 to −1.21), granisetron (−1.96, −2.74 to −1.17), tropisetron (−1.82, −2.59 to −1.05), minocycline (−1.78, −2.55 to −1.01) and memantine (−1.54, −2.28 to −0.80). Heterogeneity was low (τ = 0.119; τ2= 0.014), but the predominantly star-shaped network had zero inconsistency degrees of freedom. Overall RoB 2 judgements were low for eight trials, some concerns for 15 and high for five. Conclusions Several pharmacological and non-pharmacological add-ons showed potentially important efficacy signals. Because most nodes were informed by single small trials, direct active comparisons were scarce, inconsistency could not be evaluated and risk-of-bias concerns were common, the treatment hierarchy should be considered hypothesis-generating rather than a basis for firm clinical recommendations. Registration: PROSPERO CRD420261422218 Keywords: schizophrenia; negative symptoms; adjunctive treatment; network meta-analysis; randomized controlled trial; neurostimulation Key Points This review compares pharmacological and non-pharmacological adjuncts in adults selected for prominent or persistent negative symptoms while receiving stable antipsychotic medication. Mirtazapine, granisetron, tropisetron, minocycline and memantine had the highest P-scores, while tDCS, rTMS and body-oriented psychotherapy also showed efficacy signals versus broad control. The evidence network was sparse and star-shaped, most interventions were supported by one small trial, and inconsistency was not estimable; rankings therefore require cautious interpretation. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Use of artificial intelligence-assisted technology Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted July 31, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Comparative efficacy of pharmacological and non-pharmacological adjunctive treatments for prominent or persistent negative symptoms of schizophrenia: a systematic review and network meta-analysis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Comparative efficacy of pharmacological and non-pharmacological adjunctive treatments for prominent or persistent negative symptoms of schizophrenia: a systematic review and network meta-analysis chenkai yangyang , Jia Chen , Xiaoqiang Xiao , Yifan Li , Hongjun Du , Wenjiao Min , Xu Zhang medRxiv 2026.07.29.26359223; doi: https://doi.org/10.64898/2026.07.29.26359223 Share This Article: Copy Citation Tools Comparative efficacy of pharmacological and non-pharmacological adjunctive treatments for prominent or persistent negative symptoms of schizophrenia: a systematic review and network meta-analysis chenkai yangyang , Jia Chen , Xiaoqiang Xiao , Yifan Li , Hongjun Du , Wenjiao Min , Xu Zhang medRxiv 2026.07.29.26359223; doi: https://doi.org/10.64898/2026.07.29.26359223 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (594) Allergy and Immunology (887) Anesthesia (321) Cardiovascular Medicine (4673) Dentistry and Oral Medicine (465) Dermatology (401) Emergency Medicine (630) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1591) Epidemiology (15636) Forensic Medicine (32) Gastroenterology (1175) Genetic and Genomic Medicine (6868) Geriatric Medicine (713) Health Economics (1033) Health Informatics (4843) Health Policy (1411) Health Systems and Quality Improvement (1694) Hematology (568) HIV/AIDS (1302) Infectious Diseases (except HIV/AIDS) (16143) Intensive Care and Critical Care Medicine (1142) Medical Education (650) Medical Ethics (148) Nephrology (702) Neurology (7015) Nursing (357) Nutrition (1055) Obstetrics and Gynecology (1205) Occupational and Environmental Health (986) Oncology (3506) Ophthalmology (1014) Orthopedics (381) Otolaryngology (432) Pain Medicine (453) Palliative Medicine (135) Pathology (695) Pediatrics (1752) Pharmacology and Therapeutics (723) Primary Care Research (750) Psychiatry and Clinical Psychology (5714) Public and Global Health (9539) Radiology and Imaging (2321) Rehabilitation Medicine and Physical Therapy (1406) Respiratory Medicine (1227) Rheumatology (625) Sexual and Reproductive Health (755) Sports Medicine (567) Surgery (750) Toxicology (105) Transplantation (296) Urology (277)
## Related Clinical Research

- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years before diagnosis](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)
- [Circadian Rhythm Disturbances in Young Adults: Clinical, Functional and Genetic Correlates](https://medichelpline.com/clinical-feed/medrxiv-19-cumulative-indicators-of-circadian-rhythm-disturbance-and-its-clinical.md)
- [Genomic SEM Reveals Functionally Distinct Genetic Factors Across the Psychosis Spectrum](https://medichelpline.com/clinical-feed/medrxiv-22-parsing-the-functional-heterogeneity-of-the-psychosis-spectrum-a-clinically.md)
- [Quetiapine in Pregnancy: Reproductive Safety, Malformation Rates, and Metabolic Risks](https://medichelpline.com/clinical-feed/womens-mental-health-0-quetiapine-use-during-pregnancy-what-do-we-know-about-reproductive-safety.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.